Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach

  • Panayotis Kaloyannidis | pkaloyannidis@yahoo.gr Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  • Eshrak Al Shaibani Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  • Asif Moinnudin Medical Imaging, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  • Khalid Al Anezi Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
  • Hani Al Hashmi Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Abstract

For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Champlin R, Khouri I, Anderlini P, et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001; 27:S13-22. DOI: https://doi.org/10.1038/sj.bmt.1702864

Tsirigotis P, Danylesko I, Gkirkas K, et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone MarrowTransplant. 2016;51:1313-7. DOI: https://doi.org/10.1038/bmt.2016.129

Sala E, Crocchiolo R, Gandolfi S, et al. Bendamustine combined with donor lymphocytes infusion in Hodgkin’s lymphoma relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1444-7. DOI: https://doi.org/10.1016/j.bbmt.2014.05.024

Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311-9. DOI: https://doi.org/10.1056/NEJMoa1411087

Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016 ;34:3733-9. DOI: https://doi.org/10.1200/JCO.2016.67.3467

Kasamon YL, de Claro RA, Wang Y, et al. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Oncologist. 2017;22:585-91. DOI: https://doi.org/10.1634/theoncologist.2017-0004

Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018; 36: 1428–39.

Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125: 3393–3400. DOI: https://doi.org/10.1182/blood-2015-02-567453

LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40–8. DOI: https://doi.org/10.1182/blood-2017-11-815183

Postow MA. Managing Immune Checkpoint-Blocking Antibody Side Effects. Am Soc Clin Oncol Educ Book. 2015: 76–83. DOI: https://doi.org/10.14694/EdBook_AM.2015.35.76

Kong Y, Zhang J, Claxton DF, et al. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015;5: e330. DOI: https://doi.org/10.1038/bcj.2015.58

Norde WJ, Maas F, Hobo W, et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011;71:5111–22. DOI: https://doi.org/10.1158/0008-5472.CAN-11-0108

Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R. et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93. DOI: https://doi.org/10.1186/s13045-015-0189-2

Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R.et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221–8. DOI: https://doi.org/10.1182/blood-2017-01-761346

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.Blood. 2017;129:2471-8. DOI: https://doi.org/10.1182/blood-2016-11-749556

Godfrey J, Bishop MR, Syed S, et al. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11. DOI: https://doi.org/10.1186/s40425-017-0211-z

Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36:1428-39. DOI: https://doi.org/10.1200/JCO.2017.76.0793

Herbaux C, Merryman R, Devine S, et al. Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil. Blood. 2018; 132:9-16. DOI: https://doi.org/10.1182/blood-2018-02-811174

Onizuka M, Kojima M, Matsui K, et al. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol. 2017; 106: 141-5 DOI: https://doi.org/10.1007/s12185-017-2181-9

Published
2021-03-05
Info
Issue
Section
Case Reports
Keywords:
Allogeneic hematopoietic stem cell transplantation, Hodgkin lymphoma, programmed death-1 (PD-1) inhibitors
Statistics
  • Abstract views: 572

  • PDF: 117
  • HTML: 0
How to Cite
Kaloyannidis, P., Al Shaibani, E., Moinnudin, A., Al Anezi, K., & Al Hashmi, H. (2021). Repeated courses of escalating doses of Nivolumab in refractory Hodgkin lymphoma with recurrent relapses post allografting: A safe and effective treatment approach. Hematology Reports, 13(1). https://doi.org/10.4081/hr.2021.8780